Avalo reported study success in what’s proven to be a tough-to-treat skin disease. Elsewhere, BioNTech announced plans to close multiple plants and Madrigal picked up an RNA-based drug for MASH.
An article from
News roundup
Avalo reported study success in what’s proven to be a tough-to-treat skin disease. Elsewhere, BioNTech announced plans to close multiple plants and Madrigal picked up an RNA-based drug for MASH.
Published May 6, 2026
Getty Images
Novo Nordisk's less-bad news on its Wegovy pill boosts earnings and share price
UCB to acquire maker of antibody treatments for autoimmune diseases
Are analysts too quick to gloss over Lilly's liver case?
FDA to reconsider treatment for rare cancer after its surprise rejection
FDA revisits a rare cancer treatment it rejected a few months ago
Axsome wins FDA nod for Alzheimer's agitation
Atara, Pierre Fabre will get another shot at FDA approval, a week after Prasad's departure
Immunai expands AstraZeneca collaboration in deal worth up to $37.5 million
The biotech news you need to read today
Biotech raises $42 million to run Huntington’s disease trial
